Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...

Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need. Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.

Coming into CHEST 2024, Steven Nathan, MD, discusses how the largest unmet needs in the treatment and management of IPF and PAH include improving early diagnosis, addressing symptom management ...

PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting IPF patient ...

Please provide your email address to receive an email when new articles are posted on . Both the 18 mg and 9 mg nerandomilast groups had smaller degrees of FVC decline vs. placebo in the U.S. subgroup ...

In a recent study published in the journal JAMA Network Open, researchers evaluated the accuracy and quality of chest radiograph reports generated using artificial intelligence (AI) interpretations of ...

Regular glucosamine use is associated with a decreased risk of developing idiopathic pulmonary fibrosis (IPF).

IPF patient survey provides new insights into disease burden and patient experience one decade after the approval of the first antifibrotics for IPF Clinical abstract reviews the ability of Bayesian ...